Hepatitis B Virus clinical trials

Explore recruiting hepatitis b virus clinical trials.

Recruiting hepatitis b virus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatitis B Virus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (HEB-PEP)

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL)

France, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection

Bulgaria, Romania, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pomalidomide in people with chronic hepatitis B virus (HBV) infection: Safety and immune-enhancing effects (The PIPPI Study)

Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection

Romania, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects

Romania, Italy, Bulgaria

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Hepatitis B Virus trials by city

Hepatitis B Virus in Toronto Hepatitis B Virus in Vancouver Hepatitis B Virus in Montreal Hepatitis B Virus in Calgary Hepatitis B Virus in Edmonton Hepatitis B Virus in Ottawa Hepatitis B Virus in Winnipeg Hepatitis B Virus in Quebec City Hepatitis B Virus in Hamilton Hepatitis B Virus in Kitchener Hepatitis B Virus in London Hepatitis B Virus in Halifax Hepatitis B Virus in New York Hepatitis B Virus in Los Angeles Hepatitis B Virus in Chicago Hepatitis B Virus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease